{
    "id": 3384,
    "fullName": "MTOR E1799K",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MTOR E1799K lies within TPR repeat 13 of the Mtor protein (UniProt.org). E1799K results in similar phosphorylation of P70S6K and minimal transformation compared to wild-type in cell lines (PMID: 26432419), but confers a gain of function to the Mtor protein resulting in activation of signaling and phosphorylation of downstream targets (PMID: 24631838).",
            "references": [
                {
                    "id": 6364,
                    "pubMedId": 26432419,
                    "title": "Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432419"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2475,
        "geneSymbol": "MTOR",
        "terms": [
            "MTOR",
            "FRAP",
            "FRAP1",
            "FRAP2",
            "RAFT1",
            "RAPT1",
            "SKS"
        ]
    },
    "variant": "E1799K",
    "createDate": "02/26/2015",
    "updateDate": "03/19/2020",
    "referenceTranscriptCoordinates": {
        "id": 145165,
        "transcript": "NM_004958",
        "gDna": "chr1:g.11130747C>T",
        "cDna": "c.5395G>A",
        "protein": "p.E1799K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7443,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Apitolisib (GDC-0980) inhibited Mtor activation in transformed cells expressing MTOR E1799K in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 3193,
                "profileName": "MTOR E1799K"
            },
            "therapy": {
                "id": 750,
                "therapyName": "GDC-0980",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7441,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) inhibited Mtor activation in transformed cells over expressing MTOR E1799K in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 3193,
                "profileName": "MTOR E1799K"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7488,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human kidney cancer cell line harboring MTOR E1799K demonstrated hypersensitivity to Rapamune (sirolimus) induced growth inhibition in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 3193,
                "profileName": "MTOR E1799K"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7440,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torin 1 inhibited Mtor activation in transformed cells over expressing MTOR E1799K in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 3193,
                "profileName": "MTOR E1799K"
            },
            "therapy": {
                "id": 2247,
                "therapyName": "Torin 1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7486,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a endometrial cancer cell line harboring both MTOR R460* and E1799K demonstrated hypersensitivity to Rapamune (sirolimus) induced growth inhibition in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 25518,
                "profileName": "MTOR R460* MTOR E1799K"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3193,
            "profileName": "MTOR E1799K",
            "profileTreatmentApproaches": [
                {
                    "id": 690,
                    "name": "mTOR Inhibitor",
                    "profileName": "MTOR E1799K"
                },
                {
                    "id": 2825,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "MTOR E1799K"
                },
                {
                    "id": 2826,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "MTOR E1799K"
                }
            ]
        },
        {
            "id": 25518,
            "profileName": "MTOR R460* MTOR E1799K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 145165,
            "transcript": "NM_004958",
            "gDna": "chr1:g.11130747C>T",
            "cDna": "c.5395G>A",
            "protein": "p.E1799K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 145166,
            "transcript": "XM_005263438",
            "gDna": "chr1:g.11130747C>T",
            "cDna": "c.5395G>A",
            "protein": "p.E1799K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}